Lilly, Boehringer diabetes drug reduces cardiovascular risk in trial
 

Lilly, Boehringer diabetes drug reduces cardiovascular risk in trial
FRANKFURT (Reuters) - A clinical trial showed that diabetes drug Jardiance, co-promoted by Eli Lilly and Boehringer Ingelheim, reduces cardiovascular risk in patients with type 2 diabetes, Boehringer Ingelheim said in a statement on Thursday.
http://i1.wp.com/reuters.us.feedspor...f?resize=1%2C1http://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...v8:F7zBnMyn0Lo http://feeds.feedburner.com/~ff/reut...v8:V_sGLiPBpWU
http://feeds.feedburner.com/~r/reute...~4/mu-fRJs7Lo8